Clinical Trials
Clinical trials are essential to finding new and better ways to treat disease. By testing medicines in development, these studies help determine whether a potential therapy is safe and effective. None of this is possible without the partnership of patients who choose to participate.
Important: Budoprutug and CLYM116 are investigational therapies and have not yet been approved by any regulatory agency. Only your doctor can determine if a clinical trial may be right for you.
Budoprutug in primary membranous nephropathy (pMN)
ID: NCT07096843
Phase: Phase 2
Description: The PrisMN trial is a Phase 2, open-label, multicenter study evaluating the safety, pharmacodynamics (PD), and preliminary efficacy of three intravenous (IV) dose regimens of budoprutug in adult subjects with pMN.
Budoprutug in immune thrombocytopenia (ITP)
ID: NCT07043946
Phase: Phase 1b/2a
Description: This Phase 1b/2a, open-label, sequential-cohort, dose escalation and expansion study will evaluate the safety, tolerability, pharmacokinetics (PK), PD, and preliminary clinical effectiveness of budoprutug in subjects with ITP.
Budoprutug in systemic lupus erythematosus (SLE)
ID: NCT07011043
Phase: Phase 1b
Description: This Phase 1b, open-label single-ascending-dose study will evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and early indications of efficacy of budoprutug in SLE.
Budoprutug subcutaneous (SC) vs. IV injection in healthy volunteers
ID: NCT07090655
Phase: Phase 1
Description: This Phase 1, randomized, double-blind, placebo-controlled, single-ascending-dose study is designed to evaluate the safety, tolerability, PK and PD of budoprutug SC in normal healthy adult volunteers.